XAF-1 (Intermediate Domain) Blocking Peptide

XAF-1 (Intermediate Domain) Blocking Peptide

Product No.: X107

[product_table name="All Top" skus="X107"]

- -
- -
Target
XAF-1
Product Type
Blocking Peptide
Applications
IHC FFPE
,
N
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
14 amino acids near the amino-terminus of human XAF-1 (IN).
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Background
XAF-1 peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Antigen Details

References & Citations

1. Lockshin RA, Osborne B, and Zakeri Z. Cell death in the third millennium. Cell Death Differ. 2000; 7:2-7. 2. Cory S, Huang DCS, and Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590-607. 3. Heiser D, Labi V, Erlacher M, et al. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp. Geron. 2004; 39:1125-35. 4. Kiefer M, Brauer MJ, Powers VC, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374:736-9.
IHC FFPE
N
General Western Blot Protocol
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.